Skip to main content
Erschienen in: Urolithiasis 1/2023

01.12.2023 | Review

International Alliance of Urolithiasis (IAU) guidelines on the metabolic evaluation and medical management of urolithiasis

verfasst von: Guohua Zeng, Wei Zhu, William G. Robertson, Kristina L. Penniston, Daron Smith, Agnieszka Pozdzik, Tzevat Tefik, Domenico Prezioso, Margaret S. Pearle, Ben H. Chew, Julian Veser, Cristian Fiori, Yaoliang Deng, Michael Straub, Christian Türk, Michelle J. Semins, Kunjie Wang, Martino Marangella, Zhankui Jia, Liyuan Zhang, Zhangqun Ye, Hans-Göran Tiselius, Kemal Sarica

Erschienen in: Urolithiasis | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to construct the fourth in a series of guidelines on the treatment of urolithiasis by the International Alliance of Urolithiasis (IAU) that by providing a clinical framework for the metabolic evaluation, prevention, and follow-up of patients with urolithiasis based on the best available published literature. All recommendations were summarized following a systematic review and assessment of the literature in the PubMed database from January 1976 to June 2022. Each generated recommendation was graded using a modified GRADE methodology. Guideline recommendations were developed that addressed the following topics: initial evaluation, metabolic testing, dietary measures, medical management, and follow-up of recurrent stone formers. It was emphasized by the Panel that prevention of new stone formation is as important as the surgical removal of the stones. Although general preventive measures may be effective in reducing stone recurrence rates in some patients, specific medical and dietary management should be well considered and eventually applied in an individualized manner based on the outcomes of metabolic work-up, stone analysis and some certain patient related factors. A detailed follow-up of each case is essential depending on the metabolic activity of each individual patient.
Literatur
1.
Zurück zum Zitat Zeng G, Mai Z, Xia S et al (2017) Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int 120:109–116PubMedCrossRef Zeng G, Mai Z, Xia S et al (2017) Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int 120:109–116PubMedCrossRef
3.
Zurück zum Zitat Antonelli JA, Maalouf NM, Pearle MS, Lotan Y (2014) Use of the national health and nutrition examination survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol 66:724–729PubMedPubMedCentralCrossRef Antonelli JA, Maalouf NM, Pearle MS, Lotan Y (2014) Use of the national health and nutrition examination survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol 66:724–729PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Fryar CD, Kruszon-Moran D, Gu Q, Carroll M, Ogden CL (2021) Mean body weight, height, waist circumference, and body mass index among children and adolescents: United States, 1999–2018. Natl Health Stat Rep 1–24 Fryar CD, Kruszon-Moran D, Gu Q, Carroll M, Ogden CL (2021) Mean body weight, height, waist circumference, and body mass index among children and adolescents: United States, 1999–2018. Natl Health Stat Rep 1–24
6.
Zurück zum Zitat Morgan MSC, Pearle MS (2016) Medical management of renal stones. BMJ i52 Morgan MSC, Pearle MS (2016) Medical management of renal stones. BMJ i52
7.
Zurück zum Zitat Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926PubMedPubMedCentralCrossRef Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Gonzalez-Padilla DA, Dahm P (2021) Evidence-based urology: understanding GRADE methodology. Eur Urol Focus 7:1230–1233PubMedCrossRef Gonzalez-Padilla DA, Dahm P (2021) Evidence-based urology: understanding GRADE methodology. Eur Urol Focus 7:1230–1233PubMedCrossRef
9.
Zurück zum Zitat Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324PubMedCrossRef Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324PubMedCrossRef
10.
Zurück zum Zitat Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67:750–763PubMedCrossRef Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67:750–763PubMedCrossRef
11.
Zurück zum Zitat Robertson WG (2021) LITHOSCREEN: a comprehensive screening program and database for the assessment and treatment management of patients with kidney stones. Urolithiasis 49:387–397PubMedCrossRef Robertson WG (2021) LITHOSCREEN: a comprehensive screening program and database for the assessment and treatment management of patients with kidney stones. Urolithiasis 49:387–397PubMedCrossRef
14.
Zurück zum Zitat Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21:257–264PubMedCrossRef Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21:257–264PubMedCrossRef
15.
Zurück zum Zitat Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116:c159-171PubMedCrossRef Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116:c159-171PubMedCrossRef
16.
Zurück zum Zitat Kadlec AO, Turk TM (2013) Update on the evaluation of repeated stone formers. Curr Urol Rep 14:549–556PubMedCrossRef Kadlec AO, Turk TM (2013) Update on the evaluation of repeated stone formers. Curr Urol Rep 14:549–556PubMedCrossRef
17.
Zurück zum Zitat Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four–hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290–2298PubMedCrossRef Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four–hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290–2298PubMedCrossRef
18.
Zurück zum Zitat Pozdzik A, Maalouf N, Letavernier E et al (2019) Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017.” J Nephrol 32:681–698PubMedCrossRef Pozdzik A, Maalouf N, Letavernier E et al (2019) Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017.” J Nephrol 32:681–698PubMedCrossRef
19.
Zurück zum Zitat Laube N, Pullmann M, Hergarten S, Schmidt M, Hesse A (2003) The alteration of urine composition due to stone material present in the urinary tract. Eur Urol 44:595–599PubMedCrossRef Laube N, Pullmann M, Hergarten S, Schmidt M, Hesse A (2003) The alteration of urine composition due to stone material present in the urinary tract. Eur Urol 44:595–599PubMedCrossRef
20.
Zurück zum Zitat Hess B, Hasler-Strub U, Ackermann D, Jaeger P (1997) Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 12:1362–1368 Hess B, Hasler-Strub U, Ackermann D, Jaeger P (1997) Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 12:1362–1368
21.
Zurück zum Zitat Norman RW, Bath SS, Robertson WG, Peacock M (1984) When should patients with symptomatic urinary stone disease be evaluated metabolically? J Urol 132:1137–1139PubMedCrossRef Norman RW, Bath SS, Robertson WG, Peacock M (1984) When should patients with symptomatic urinary stone disease be evaluated metabolically? J Urol 132:1137–1139PubMedCrossRef
22.
Zurück zum Zitat Ferraz RRN, Baxmann AC, Ferreira LG, Nishiura JL, Siliano PR, Gomes SA, Moreira SRS, Heilberg IP (2006) Preservation of urine samples for metabolic evaluation of stone-forming patients. Urol Res 34:329–337PubMedCrossRef Ferraz RRN, Baxmann AC, Ferreira LG, Nishiura JL, Siliano PR, Gomes SA, Moreira SRS, Heilberg IP (2006) Preservation of urine samples for metabolic evaluation of stone-forming patients. Urol Res 34:329–337PubMedCrossRef
23.
Zurück zum Zitat Yilmaz G, Yilmaz F, Haklıgör A, Yucel D (2008) Are preservatives necessary in 24-hour urine measurements? Clin Biochem 41:899–901PubMedCrossRef Yilmaz G, Yilmaz F, Haklıgör A, Yucel D (2008) Are preservatives necessary in 24-hour urine measurements? Clin Biochem 41:899–901PubMedCrossRef
24.
Zurück zum Zitat Gambaro G, Croppi E, Coe F et al (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29:715–734PubMedPubMedCentralCrossRef Gambaro G, Croppi E, Coe F et al (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29:715–734PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Sromicki J, Kacl G, Föhl M, Hess B (2022) Prospective long-term evaluation of incomplete distal renal tubular acidosis in idiopathic calcium nephrolithiasis diagnosed by low-dose NH4CL loading – gender prevalences and impact of alkali treatment. J Nephrol 35:1619–1626PubMedPubMedCentralCrossRef Sromicki J, Kacl G, Föhl M, Hess B (2022) Prospective long-term evaluation of incomplete distal renal tubular acidosis in idiopathic calcium nephrolithiasis diagnosed by low-dose NH4CL loading – gender prevalences and impact of alkali treatment. J Nephrol 35:1619–1626PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Nayan M, Elkoushy MA, Andonian S (2012) Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. Uric Acid 6:5 Nayan M, Elkoushy MA, Andonian S (2012) Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. Uric Acid 6:5
27.
Zurück zum Zitat Parks JH, Goldfisher E, Asplin JR, Coe FL (2002) A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 167:1607–1612PubMedCrossRef Parks JH, Goldfisher E, Asplin JR, Coe FL (2002) A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 167:1607–1612PubMedCrossRef
28.
Zurück zum Zitat Healy KA, Hubosky SG, Bagley DH (2013) 24-Hour Urine Collection in the metabolic evaluation of stone formers: is one study adequate? J Endourol 27:374–378PubMedCrossRef Healy KA, Hubosky SG, Bagley DH (2013) 24-Hour Urine Collection in the metabolic evaluation of stone formers: is one study adequate? J Endourol 27:374–378PubMedCrossRef
29.
Zurück zum Zitat Parks JH, Coward M, Coe FL (1997) Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51:894–900PubMedCrossRef Parks JH, Coward M, Coe FL (1997) Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51:894–900PubMedCrossRef
30.
Zurück zum Zitat Borghi L, Guerra A, Meschi T, Briganti A, Schianchi T, Allegri F, Novarini A (1999) Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int 55:1041–1050PubMedCrossRef Borghi L, Guerra A, Meschi T, Briganti A, Schianchi T, Allegri F, Novarini A (1999) Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int 55:1041–1050PubMedCrossRef
31.
Zurück zum Zitat Yuzhakov S, Steadman SD, Otto BJ, Bird VG, Canales BK (2021) 24-Hour urine calcium oxalate supersaturation risk correlates with computerized tomography volumetric calcium oxalate stone growth. J Urol 206:1438–1444PubMedCrossRef Yuzhakov S, Steadman SD, Otto BJ, Bird VG, Canales BK (2021) 24-Hour urine calcium oxalate supersaturation risk correlates with computerized tomography volumetric calcium oxalate stone growth. J Urol 206:1438–1444PubMedCrossRef
32.
Zurück zum Zitat Prochaska M, Taylor E, Ferraro PM, Curhan G (2018) Relative supersaturation of 24-hour urine and likelihood of kidney stones. J Urol 199:1262–1266PubMedCrossRef Prochaska M, Taylor E, Ferraro PM, Curhan G (2018) Relative supersaturation of 24-hour urine and likelihood of kidney stones. J Urol 199:1262–1266PubMedCrossRef
33.
Zurück zum Zitat Tiselius HG (1991) Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 47:255–259PubMedCrossRef Tiselius HG (1991) Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 47:255–259PubMedCrossRef
34.
Zurück zum Zitat Tiselius H-G (1984) A simplified estimate of the ion-activity product of calcium phosphate in urine. Eur Urol 10:191–195PubMedCrossRef Tiselius H-G (1984) A simplified estimate of the ion-activity product of calcium phosphate in urine. Eur Urol 10:191–195PubMedCrossRef
35.
Zurück zum Zitat Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130:1115–1118PubMedCrossRef Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130:1115–1118PubMedCrossRef
36.
Zurück zum Zitat Tiselius HG (1989) Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers. Eur Urol 16:48–50PubMedCrossRef Tiselius HG (1989) Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers. Eur Urol 16:48–50PubMedCrossRef
37.
Zurück zum Zitat Omar M, Sarkissian C, Jianbo L, Calle J, Monga M, Omar M, Sarkissian C, Jianbo L, Calle J, Monga M (2016) Dipstick spot urine pH does not accurately represent 24 hour urine PH measured by an electrode. Int Braz J Urol 42:546–549PubMedPubMedCentralCrossRef Omar M, Sarkissian C, Jianbo L, Calle J, Monga M, Omar M, Sarkissian C, Jianbo L, Calle J, Monga M (2016) Dipstick spot urine pH does not accurately represent 24 hour urine PH measured by an electrode. Int Braz J Urol 42:546–549PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Ferraro PM, Lopez F, Petrarulo M, Barbarini S, Curhan GC, Marangella M, Taylor EN (2022) Estimating 24-hour urinary excretion using spot urine measurements in kidney stone formers. Nephrol Dial Transplant 37:2171–2179PubMedPubMedCentralCrossRef Ferraro PM, Lopez F, Petrarulo M, Barbarini S, Curhan GC, Marangella M, Taylor EN (2022) Estimating 24-hour urinary excretion using spot urine measurements in kidney stone formers. Nephrol Dial Transplant 37:2171–2179PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Hong YH, Dublin N, Razack AH, Mohd MA, Husain R (2010) Twenty-four hour and spot urine metabolic evaluations: correlations versus agreements. Urology 75:1294–1298PubMedCrossRef Hong YH, Dublin N, Razack AH, Mohd MA, Husain R (2010) Twenty-four hour and spot urine metabolic evaluations: correlations versus agreements. Urology 75:1294–1298PubMedCrossRef
40.
Zurück zum Zitat Williams JC, Gambaro G, Rodgers A et al (2021) Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis 49:1–16PubMedCrossRef Williams JC, Gambaro G, Rodgers A et al (2021) Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis 49:1–16PubMedCrossRef
41.
Zurück zum Zitat Daudon M, Hennequin C, Boujelben G, Lacour B, Jungers P (2005) Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int 67:1934–1943PubMedCrossRef Daudon M, Hennequin C, Boujelben G, Lacour B, Jungers P (2005) Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int 67:1934–1943PubMedCrossRef
42.
Zurück zum Zitat Daudon M, Cohen-Solal F, Barbey F, Gagnadoux M-F, Knebelmann B, Jungers P (2003) Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res 31:207–211PubMedCrossRef Daudon M, Cohen-Solal F, Barbey F, Gagnadoux M-F, Knebelmann B, Jungers P (2003) Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res 31:207–211PubMedCrossRef
43.
Zurück zum Zitat Robert M, Boularan AM, Delbos O, Monnier L, Grasset D (1996) Evaluation of the risk of stone formation: study on crystalluria in patients with recurrent calcium oxalate urolithiasis. Eur Urol 29:456–461PubMedCrossRef Robert M, Boularan AM, Delbos O, Monnier L, Grasset D (1996) Evaluation of the risk of stone formation: study on crystalluria in patients with recurrent calcium oxalate urolithiasis. Eur Urol 29:456–461PubMedCrossRef
44.
Zurück zum Zitat Kourambas J, Aslan P, Teh CL, Mathias BJ, Preminger GM (2001) Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol 15:181–186PubMedCrossRef Kourambas J, Aslan P, Teh CL, Mathias BJ, Preminger GM (2001) Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol 15:181–186PubMedCrossRef
45.
Zurück zum Zitat Pak CYC, Poindexter JR, Adams-Huet B, Pearle MS (2003) Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115:26–32PubMedCrossRef Pak CYC, Poindexter JR, Adams-Huet B, Pearle MS (2003) Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115:26–32PubMedCrossRef
46.
Zurück zum Zitat Gilad R, Williams JC, Usman KD, Holland R, Golan S, Tor R, Lifshitz D (2017) Interpreting the results of chemical stone analysis in the era of modern stone analysis techniques. J Nephrol 30:135–140PubMedCrossRef Gilad R, Williams JC, Usman KD, Holland R, Golan S, Tor R, Lifshitz D (2017) Interpreting the results of chemical stone analysis in the era of modern stone analysis techniques. J Nephrol 30:135–140PubMedCrossRef
47.
Zurück zum Zitat Taheri M, Basiri A, Taheri F, Khoshdel AR, Fallah MA, Pur Nourbakhsh F (2019) The agreement between current stone analysis techniques and SEM-EDAX in urolithiasis. Urol J 16:6–11PubMed Taheri M, Basiri A, Taheri F, Khoshdel AR, Fallah MA, Pur Nourbakhsh F (2019) The agreement between current stone analysis techniques and SEM-EDAX in urolithiasis. Urol J 16:6–11PubMed
48.
Zurück zum Zitat Pozdzik A, Van Haute C, Maalouf N, Letavernier E, Williams JC, Sakhaee K (2021) “Trust my morphology”, the key message from a kidney stone. Urolithiasis 49:493–494PubMedPubMedCentralCrossRef Pozdzik A, Van Haute C, Maalouf N, Letavernier E, Williams JC, Sakhaee K (2021) “Trust my morphology”, the key message from a kidney stone. Urolithiasis 49:493–494PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Taguchi K, Yasui T, Milliner DS, Hoppe B, Chi T (2017) Genetic risk factors for idiopathic urolithiasis: a systematic review of the literature and causal network analysis. Eur Urol Focus 3:72–81PubMedCrossRef Taguchi K, Yasui T, Milliner DS, Hoppe B, Chi T (2017) Genetic risk factors for idiopathic urolithiasis: a systematic review of the literature and causal network analysis. Eur Urol Focus 3:72–81PubMedCrossRef
50.
Zurück zum Zitat Cogal AG, Arroyo J, Shah RJ et al (2021) Comprehensive genetic analysis reveals complexity of monogenic urinary stone disease. Kidney Int Rep 6:2862–2884PubMedPubMedCentralCrossRef Cogal AG, Arroyo J, Shah RJ et al (2021) Comprehensive genetic analysis reveals complexity of monogenic urinary stone disease. Kidney Int Rep 6:2862–2884PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Robertson WG (2016) Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease. Urolithiasis 44:9–26PubMedCrossRef Robertson WG (2016) Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease. Urolithiasis 44:9–26PubMedCrossRef
52.
Zurück zum Zitat Ferraro PM, Bargagli M, Trinchieri A, Gambaro G (2020) Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets. Nutrients 12:E779CrossRef Ferraro PM, Bargagli M, Trinchieri A, Gambaro G (2020) Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets. Nutrients 12:E779CrossRef
53.
Zurück zum Zitat Littlejohns TJ, Neal NL, Bradbury KE, Heers H, Allen NE, Turney BW (2020) Fluid intake and dietary factors and the risk of incident kidney stones in UK biobank: a population-based prospective cohort study. Eur Urol Focus 6:752–761PubMedCrossRef Littlejohns TJ, Neal NL, Bradbury KE, Heers H, Allen NE, Turney BW (2020) Fluid intake and dietary factors and the risk of incident kidney stones in UK biobank: a population-based prospective cohort study. Eur Urol Focus 6:752–761PubMedCrossRef
54.
Zurück zum Zitat Taylor EN, Curhan GC (2008) Fructose consumption and the risk of kidney stones. Kidney Int 73:207–212PubMedCrossRef Taylor EN, Curhan GC (2008) Fructose consumption and the risk of kidney stones. Kidney Int 73:207–212PubMedCrossRef
55.
Zurück zum Zitat Messa P, Marangella M, Paganin L, Codardini M, Cruciatti A, Turrin D, Filiberto Z (1977) Different dietary calcium intake and relative supersaturation of calcium oxalate in the urine of patients forming renal stones. Clin Sci Lond Engl 93:257–263CrossRef Messa P, Marangella M, Paganin L, Codardini M, Cruciatti A, Turrin D, Filiberto Z (1977) Different dietary calcium intake and relative supersaturation of calcium oxalate in the urine of patients forming renal stones. Clin Sci Lond Engl 93:257–263CrossRef
56.
Zurück zum Zitat Hess B (1998) High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 13:2241–2247PubMedCrossRef Hess B (1998) High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 13:2241–2247PubMedCrossRef
57.
58.
Zurück zum Zitat Franceschi VR, Nakata PA (2005) Calcium oxalate in plants: formation and function. Annu Rev Plant Biol 56:41–71PubMedCrossRef Franceschi VR, Nakata PA (2005) Calcium oxalate in plants: formation and function. Annu Rev Plant Biol 56:41–71PubMedCrossRef
59.
Zurück zum Zitat Lange JN, Wood KD, Mufarrij PW, Callahan MF, Easter L, Knight J, Holmes RP, Assimos DG (2012) The impact of dietary calcium and oxalate ratios on stone risk. Urology 79:1226–1229PubMedCrossRef Lange JN, Wood KD, Mufarrij PW, Callahan MF, Easter L, Knight J, Holmes RP, Assimos DG (2012) The impact of dietary calcium and oxalate ratios on stone risk. Urology 79:1226–1229PubMedCrossRef
60.
Zurück zum Zitat Giannini S, Nobile M, Sartori L, Dalle Carbonare L, Ciuffreda M, Corrò P, D’Angelo A, Calò L, Crepaldi G (1999) Acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Am J Clin Nutr 69:267–271PubMedCrossRef Giannini S, Nobile M, Sartori L, Dalle Carbonare L, Ciuffreda M, Corrò P, D’Angelo A, Calò L, Crepaldi G (1999) Acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Am J Clin Nutr 69:267–271PubMedCrossRef
62.
Zurück zum Zitat Hess B (1998) “Bad dietary habits” and recurrent calcium oxalate nephrolithiasis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 13:1033–1038 Hess B (1998) “Bad dietary habits” and recurrent calcium oxalate nephrolithiasis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 13:1033–1038
63.
Zurück zum Zitat Ferraro PM, Taylor EN, Gambaro G, Curhan GC (2017) Vitamin D intake and the risk of incident kidney stones. J Urol 197:405–410PubMedCrossRef Ferraro PM, Taylor EN, Gambaro G, Curhan GC (2017) Vitamin D intake and the risk of incident kidney stones. J Urol 197:405–410PubMedCrossRef
64.
Zurück zum Zitat Ferraro PM, Curhan GC, Gambaro G, Taylor EN (2016) Total, dietary, and supplemental vitamin c intake and risk of incident kidney stones. Am J Kidney Dis Off J Natl Kidney Found 67:400–407CrossRef Ferraro PM, Curhan GC, Gambaro G, Taylor EN (2016) Total, dietary, and supplemental vitamin c intake and risk of incident kidney stones. Am J Kidney Dis Off J Natl Kidney Found 67:400–407CrossRef
65.
Zurück zum Zitat Thomas LDK, Elinder C-G, Tiselius H-G, Wolk A, Akesson A (2013) Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med 173:386–388PubMedCrossRef Thomas LDK, Elinder C-G, Tiselius H-G, Wolk A, Akesson A (2013) Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med 173:386–388PubMedCrossRef
66.
Zurück zum Zitat Traxer O, Huet B, Poindexter J, Pak CYC, Pearle MS (2003) Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 170:397–401PubMedCrossRef Traxer O, Huet B, Poindexter J, Pak CYC, Pearle MS (2003) Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 170:397–401PubMedCrossRef
67.
Zurück zum Zitat Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ (1998) Body size and risk of kidney stones. J Am Soc Nephrol JASN 9:1645–1652PubMedCrossRef Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ (1998) Body size and risk of kidney stones. J Am Soc Nephrol JASN 9:1645–1652PubMedCrossRef
68.
Zurück zum Zitat Sorensen MD, Chi T, Shara NM et al (2014) Activity, energy intake, obesity, and the risk of incident kidney stones in postmenopausal women: a report from the women’s health initiative. J Am Soc Nephrol JASN 25:362PubMedCrossRef Sorensen MD, Chi T, Shara NM et al (2014) Activity, energy intake, obesity, and the risk of incident kidney stones in postmenopausal women: a report from the women’s health initiative. J Am Soc Nephrol JASN 25:362PubMedCrossRef
69.
Zurück zum Zitat Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Ouellette J, Monga M (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158:535–543PubMedCrossRef Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Ouellette J, Monga M (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158:535–543PubMedCrossRef
70.
Zurück zum Zitat Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139:679–684PubMedCrossRef Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139:679–684PubMedCrossRef
71.
Zurück zum Zitat Vigen R, Weideman RA, Reilly RF (2011) Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol 43:813–819PubMedCrossRef Vigen R, Weideman RA, Reilly RF (2011) Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol 43:813–819PubMedCrossRef
72.
Zurück zum Zitat Alon US (2018) The effects of diuretics on mineral and bone metabolism. Pediatr Endocrinol Rev 15:291–297PubMed Alon US (2018) The effects of diuretics on mineral and bone metabolism. Pediatr Endocrinol Rev 15:291–297PubMed
73.
Zurück zum Zitat Nijenhuis T, Vallon V, van der Kemp AWCM, Loffing J, Hoenderop JGJ, Bindels RJM (2005) Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 115:1651–1658PubMedPubMedCentralCrossRef Nijenhuis T, Vallon V, van der Kemp AWCM, Loffing J, Hoenderop JGJ, Bindels RJM (2005) Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 115:1651–1658PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Martínez García M, Trincado Aznar P, Pérez Fernández L, Azcona Monreal I, López Alaminos ME, Acha Pérez J, Albero Gamboa R (2019) A comparison of induced effects on urinary calcium by thiazides and different dietary salt doses: Implications in clinical practice. Nefrologia 39:73–79PubMedCrossRef Martínez García M, Trincado Aznar P, Pérez Fernández L, Azcona Monreal I, López Alaminos ME, Acha Pérez J, Albero Gamboa R (2019) A comparison of induced effects on urinary calcium by thiazides and different dietary salt doses: Implications in clinical practice. Nefrologia 39:73–79PubMedCrossRef
75.
Zurück zum Zitat Pak CYC, Sakhaee K, Moe OW, Poindexter J, Adams-Huet B, with Colleagues (2011) Defining hypercalciuria in nephrolithiasis. Kidney Int 80:777–782 Pak CYC, Sakhaee K, Moe OW, Poindexter J, Adams-Huet B, with Colleagues (2011) Defining hypercalciuria in nephrolithiasis. Kidney Int 80:777–782
76.
Zurück zum Zitat Song Y, Hernandez N, Shoag J, Goldfarb DS, Eisner BH (2016) Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis. Urolithiasis 44:145–148PubMedCrossRef Song Y, Hernandez N, Shoag J, Goldfarb DS, Eisner BH (2016) Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis. Urolithiasis 44:145–148PubMedCrossRef
77.
Zurück zum Zitat Kessler T, Hesse A (2000) Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects. Br J Nutr 84:865–871PubMedCrossRef Kessler T, Hesse A (2000) Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects. Br J Nutr 84:865–871PubMedCrossRef
78.
Zurück zum Zitat Pinheiro VB, Baxmann AC, Tiselius H-G, Heilberg IP (2013) The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology 82:33–37PubMedCrossRef Pinheiro VB, Baxmann AC, Tiselius H-G, Heilberg IP (2013) The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology 82:33–37PubMedCrossRef
79.
Zurück zum Zitat Caudarella R, Vescini F, Buffa A, Stefoni S (2003) Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci J Virtual Libr 8:s1084-1106CrossRef Caudarella R, Vescini F, Buffa A, Stefoni S (2003) Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci J Virtual Libr 8:s1084-1106CrossRef
80.
Zurück zum Zitat Leslie SW, Bashir K (2022) Hypocitraturia and renal calculi. StatPearls Leslie SW, Bashir K (2022) Hypocitraturia and renal calculi. StatPearls
81.
Zurück zum Zitat Anaizi NH, Cohen JJ, Black AJ, Wertheim SJ (1986) Renal tissue citrate: independence from citrate utilization, reabsorption, and pH. Am J Physiol 251:F547-561PubMed Anaizi NH, Cohen JJ, Black AJ, Wertheim SJ (1986) Renal tissue citrate: independence from citrate utilization, reabsorption, and pH. Am J Physiol 251:F547-561PubMed
83.
Zurück zum Zitat Asplin JR (2016) The management of patients with enteric hyperoxaluria. Urolithiasis 44:33–43PubMedCrossRef Asplin JR (2016) The management of patients with enteric hyperoxaluria. Urolithiasis 44:33–43PubMedCrossRef
84.
Zurück zum Zitat Sromicki J, Hess B (2020) Simple dietary advice targeting five urinary parameters reduces urinary supersaturation in idiopathic calcium oxalate stone formers. Urolithiasis 48:425–433PubMedPubMedCentralCrossRef Sromicki J, Hess B (2020) Simple dietary advice targeting five urinary parameters reduces urinary supersaturation in idiopathic calcium oxalate stone formers. Urolithiasis 48:425–433PubMedPubMedCentralCrossRef
85.
Zurück zum Zitat Domrongkitchaiporn S, Sopassathit W, Stitchantrakul W, Prapaipanich S, Ingsathit A, Rajatanavin R (2004) Schedule of taking calcium supplement and the risk of nephrolithiasis. Kidney Int 65:1835–1841PubMedCrossRef Domrongkitchaiporn S, Sopassathit W, Stitchantrakul W, Prapaipanich S, Ingsathit A, Rajatanavin R (2004) Schedule of taking calcium supplement and the risk of nephrolithiasis. Kidney Int 65:1835–1841PubMedCrossRef
86.
Zurück zum Zitat Zimmermann DJ, Voss S, von Unruh GE, Hesse A (2005) Importance of magnesium in absorption and excretion of oxalate. Urol Int 74:262–267PubMedCrossRef Zimmermann DJ, Voss S, von Unruh GE, Hesse A (2005) Importance of magnesium in absorption and excretion of oxalate. Urol Int 74:262–267PubMedCrossRef
87.
Zurück zum Zitat Liebman M, Costa G (2000) Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 163:1565–1569PubMedCrossRef Liebman M, Costa G (2000) Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 163:1565–1569PubMedCrossRef
88.
Zurück zum Zitat Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG (2011) Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol 186:135–139PubMedPubMedCentralCrossRef Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG (2011) Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol 186:135–139PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Mydlík M, Derzsiová K (2010) Vitamin B6 and oxalic acid in clinical nephrology. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found 20:S95-102 Mydlík M, Derzsiová K (2010) Vitamin B6 and oxalic acid in clinical nephrology. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found 20:S95-102
90.
Zurück zum Zitat Espino-Grosso P, Monsour C, Canales BK (2019) The effect of calcium and vitamin B6 supplementation on oxalate excretion in a rodent gastric bypass model of enteric hyperoxaluria. Urology 124:310.e9-310.e14PubMedCrossRef Espino-Grosso P, Monsour C, Canales BK (2019) The effect of calcium and vitamin B6 supplementation on oxalate excretion in a rodent gastric bypass model of enteric hyperoxaluria. Urology 124:310.e9-310.e14PubMedCrossRef
91.
Zurück zum Zitat Okada A, Matsumoto T, Ohshima H et al (2022) Bisphosphonate use may reduce the risk of urolithiasis in astronauts on long-term spaceflights. JBMR Plus 6:e10550PubMedCrossRef Okada A, Matsumoto T, Ohshima H et al (2022) Bisphosphonate use may reduce the risk of urolithiasis in astronauts on long-term spaceflights. JBMR Plus 6:e10550PubMedCrossRef
92.
Zurück zum Zitat Maalouf NM, Cameron MA, Moe OW, Sakhaee K (2004) Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13:181–189PubMedCrossRef Maalouf NM, Cameron MA, Moe OW, Sakhaee K (2004) Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13:181–189PubMedCrossRef
94.
Zurück zum Zitat Kamphuis GM, Wouter van Hattum J, de Bie P, Somani BK (2019) Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review. Transl Androl Urol 8:S448–S456PubMedPubMedCentralCrossRef Kamphuis GM, Wouter van Hattum J, de Bie P, Somani BK (2019) Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review. Transl Androl Urol 8:S448–S456PubMedPubMedCentralCrossRef
95.
Zurück zum Zitat Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60:378–382PubMedCrossRef Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60:378–382PubMedCrossRef
96.
Zurück zum Zitat Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65:386–392PubMedCrossRef Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65:386–392PubMedCrossRef
97.
Zurück zum Zitat Bobulescu IA, Park SK, Xu LHR, Blanco F, Poindexter J, Adams-Huet B, Davidson TL, Sakhaee K, Maalouf NM, Moe OW (2019) Net acid excretion and urinary organic anions in idiopathic uric acid nephrolithiasis. Clin J Am Soc Nephrol CJASN 14:411–420PubMedCrossRef Bobulescu IA, Park SK, Xu LHR, Blanco F, Poindexter J, Adams-Huet B, Davidson TL, Sakhaee K, Maalouf NM, Moe OW (2019) Net acid excretion and urinary organic anions in idiopathic uric acid nephrolithiasis. Clin J Am Soc Nephrol CJASN 14:411–420PubMedCrossRef
98.
Zurück zum Zitat Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13:679–685PubMedCrossRef Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13:679–685PubMedCrossRef
99.
Zurück zum Zitat Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L (2013) Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol CJASN 8:1960–1967PubMedCrossRef Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L (2013) Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol CJASN 8:1960–1967PubMedCrossRef
100.
Zurück zum Zitat Dion M, Ankawi G, Chew B, Paterson R, Sultan N, Hoddinott P, Razvi H (2016) CUA guideline on the evaluation and medical management of the kidney stone patient – 2016 update. Can Urol Assoc J 10:E347–E358PubMedPubMedCentralCrossRef Dion M, Ankawi G, Chew B, Paterson R, Sultan N, Hoddinott P, Razvi H (2016) CUA guideline on the evaluation and medical management of the kidney stone patient – 2016 update. Can Urol Assoc J 10:E347–E358PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Moussa M, Papatsoris AG, Abou Chakra M, Moussa Y (2020) Update on cystine stones: current and future concepts in treatment. Intractable Rare Dis Res 9:71–78PubMedPubMedCentralCrossRef Moussa M, Papatsoris AG, Abou Chakra M, Moussa Y (2020) Update on cystine stones: current and future concepts in treatment. Intractable Rare Dis Res 9:71–78PubMedPubMedCentralCrossRef
102.
Zurück zum Zitat Sterrett SP, Penniston KL, Wolf JS, Nakada SY (2008) Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72:278–281PubMedCrossRef Sterrett SP, Penniston KL, Wolf JS, Nakada SY (2008) Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72:278–281PubMedCrossRef
103.
Zurück zum Zitat Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136:1003–1008PubMedCrossRef Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136:1003–1008PubMedCrossRef
104.
Zurück zum Zitat Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T (2016) EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 69:468–474PubMedCrossRef Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T (2016) EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 69:468–474PubMedCrossRef
105.
Zurück zum Zitat Das P, Gupta G, Velu V, Awasthi R, Dua K, Malipeddi H (2017) Formation of struvite urinary stones and approaches towards the inhibition-A review. Biomed Pharmacother Biomedecine Pharmacother 96:361–370CrossRef Das P, Gupta G, Velu V, Awasthi R, Dua K, Malipeddi H (2017) Formation of struvite urinary stones and approaches towards the inhibition-A review. Biomed Pharmacother Biomedecine Pharmacother 96:361–370CrossRef
106.
Zurück zum Zitat Wang LP, Wong HY, Griffith DP (1997) Treatment options in struvite stones. Urol Clin North Am 24:149–162PubMedCrossRef Wang LP, Wong HY, Griffith DP (1997) Treatment options in struvite stones. Urol Clin North Am 24:149–162PubMedCrossRef
107.
Zurück zum Zitat Bichler K-H, Eipper E, Naber K, Braun V, Zimmermann R, Lahme S (2002) Urinary infection stones. Int J Antimicrob Agents 19:488–498PubMedCrossRef Bichler K-H, Eipper E, Naber K, Braun V, Zimmermann R, Lahme S (2002) Urinary infection stones. Int J Antimicrob Agents 19:488–498PubMedCrossRef
108.
Zurück zum Zitat Flannigan R, Choy WH, Chew B, Lange D (2014) Renal struvite stones–pathogenesis, microbiology, and management strategies. Nat Rev Urol 11:333–341PubMedCrossRef Flannigan R, Choy WH, Chew B, Lange D (2014) Renal struvite stones–pathogenesis, microbiology, and management strategies. Nat Rev Urol 11:333–341PubMedCrossRef
109.
Zurück zum Zitat Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17:308–315PubMedCrossRef Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17:308–315PubMedCrossRef
110.
Zurück zum Zitat Zisman AL (2017) Effectiveness of treatment modalities on kidney stone recurrence. Clin J Am Soc Nephrol CJASN 12:1699–1708PubMedCrossRef Zisman AL (2017) Effectiveness of treatment modalities on kidney stone recurrence. Clin J Am Soc Nephrol CJASN 12:1699–1708PubMedCrossRef
111.
Zurück zum Zitat Williams JJ, Rodman JS, Peterson CM (1984) A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med 311:760–764PubMedCrossRef Williams JJ, Rodman JS, Peterson CM (1984) A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med 311:760–764PubMedCrossRef
112.
Zurück zum Zitat Griffith DP, Khonsari F, Skurnick JH, James KE (1988) A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol 140:318–324PubMedCrossRef Griffith DP, Khonsari F, Skurnick JH, James KE (1988) A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol 140:318–324PubMedCrossRef
113.
Zurück zum Zitat Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N (1991) Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 20:243–247PubMedCrossRef Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N (1991) Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 20:243–247PubMedCrossRef
114.
115.
Zurück zum Zitat Shee K, Stoller ML (2022) Perspectives in primary hyperoxaluria — historical, current and future clinical interventions. Nat Rev Urol 19:137–146PubMedCrossRef Shee K, Stoller ML (2022) Perspectives in primary hyperoxaluria — historical, current and future clinical interventions. Nat Rev Urol 19:137–146PubMedCrossRef
116.
Zurück zum Zitat Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol CJASN 9:468–477PubMedCrossRef Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol CJASN 9:468–477PubMedCrossRef
118.
Zurück zum Zitat Garrelfs SF, Frishberg Y, Hulton SA et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216–1226PubMedCrossRef Garrelfs SF, Frishberg Y, Hulton SA et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216–1226PubMedCrossRef
120.
Zurück zum Zitat Shavit L, Chen L, Ahmed F, Ferraro PM, Moochhala S, Walsh SB, Unwin R (2016) Selective screening for distal renal tubular acidosis in recurrent kidney stone formers: initial experience and comparison of the simultaneous furosemide and fludrocortisone test with the short ammonium chloride test. Nephrol Dial Transplant 31:1870–1876PubMedCrossRef Shavit L, Chen L, Ahmed F, Ferraro PM, Moochhala S, Walsh SB, Unwin R (2016) Selective screening for distal renal tubular acidosis in recurrent kidney stone formers: initial experience and comparison of the simultaneous furosemide and fludrocortisone test with the short ammonium chloride test. Nephrol Dial Transplant 31:1870–1876PubMedCrossRef
122.
Zurück zum Zitat Preminger GM, Sakhaee K, Skurla C, Pak CY (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134:20–23PubMedCrossRef Preminger GM, Sakhaee K, Skurla C, Pak CY (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134:20–23PubMedCrossRef
123.
Zurück zum Zitat Fulgham PF, Assimos DG, Pearle MS, Preminger GM (2013) Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment. J Urol 189:1203–1213PubMedCrossRef Fulgham PF, Assimos DG, Pearle MS, Preminger GM (2013) Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment. J Urol 189:1203–1213PubMedCrossRef
124.
Zurück zum Zitat Wollin DA, Kaplan AG, Preminger GM, Ferraro PM, Nouvenne A, Tasca A, Croppi E, Gambaro G, Heilberg IP (2018) Defining metabolic activity of nephrolithiasis – appropriate evaluation and follow-up of stone formers. Asian J Urol 5:235PubMedPubMedCentralCrossRef Wollin DA, Kaplan AG, Preminger GM, Ferraro PM, Nouvenne A, Tasca A, Croppi E, Gambaro G, Heilberg IP (2018) Defining metabolic activity of nephrolithiasis – appropriate evaluation and follow-up of stone formers. Asian J Urol 5:235PubMedPubMedCentralCrossRef
126.
Zurück zum Zitat Jiang P, Xie L, Arada R, Patel RM, Landman J, Clayman RV (2021) Qualitative review of clinical guidelines for medical and surgical management of urolithiasis: consensus and controversy 2020. J Urol 205:999–1008PubMedCrossRef Jiang P, Xie L, Arada R, Patel RM, Landman J, Clayman RV (2021) Qualitative review of clinical guidelines for medical and surgical management of urolithiasis: consensus and controversy 2020. J Urol 205:999–1008PubMedCrossRef
127.
Zurück zum Zitat Leslie SW, Sajjad H, Bashir K (2022) 24-Hour Urine Testing for Nephrolithiasis: Interpretation Guideline. StatPearls Leslie SW, Sajjad H, Bashir K (2022) 24-Hour Urine Testing for Nephrolithiasis: Interpretation Guideline. StatPearls
128.
Zurück zum Zitat Li S, Iremashvili V, Vernez SL, Penniston KL, Jhagroo RA, Best SL, Hedican SP, Nakada SY (2021) Effect of stone composition on surgical stone recurrence: single center longitudinal analysis. Can J Urol 28:10744–10749PubMed Li S, Iremashvili V, Vernez SL, Penniston KL, Jhagroo RA, Best SL, Hedican SP, Nakada SY (2021) Effect of stone composition on surgical stone recurrence: single center longitudinal analysis. Can J Urol 28:10744–10749PubMed
129.
Zurück zum Zitat Zeng G, Zhao Z, Wu W, Ou L, Liang Y, Yuan J (2014) Interconversion of stone composition profiles from two recurrent stone episodes in stone formers. Clin Chem Lab Med 52:1019–1024PubMedCrossRef Zeng G, Zhao Z, Wu W, Ou L, Liang Y, Yuan J (2014) Interconversion of stone composition profiles from two recurrent stone episodes in stone formers. Clin Chem Lab Med 52:1019–1024PubMedCrossRef
Metadaten
Titel
International Alliance of Urolithiasis (IAU) guidelines on the metabolic evaluation and medical management of urolithiasis
verfasst von
Guohua Zeng
Wei Zhu
William G. Robertson
Kristina L. Penniston
Daron Smith
Agnieszka Pozdzik
Tzevat Tefik
Domenico Prezioso
Margaret S. Pearle
Ben H. Chew
Julian Veser
Cristian Fiori
Yaoliang Deng
Michael Straub
Christian Türk
Michelle J. Semins
Kunjie Wang
Martino Marangella
Zhankui Jia
Liyuan Zhang
Zhangqun Ye
Hans-Göran Tiselius
Kemal Sarica
Publikationsdatum
01.12.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 1/2023
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-022-01387-2

Weitere Artikel der Ausgabe 1/2023

Urolithiasis 1/2023 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.